I know, I know they had a lot of debt, but still I think there were other options to filing for Bankruptcy. So what were they? Well first, its important to note that Vion’s situation was at best really really terrible, but still most pharma companies can get financing when they need it. So let’s take a quick look at what exactly Vion had to offer possible bailout investors.
Onrigin for AML
Seriously, this was actually a very viable product in terms of » Read more: What Vion Should Have Done
So this isn’t really big new to anybody that follows Vion’s lead AML drug Onrigin. The company received a vote back in September of 2009 by the FDA’s ODAC for the company to run another clinical trial for the drug. I know the PDUFA date was set for December 12, 2009, but today is december 14, 2009. The FDA has had 3 full months to issue a timely response, but they are late again » Read more: Vion Receives their Complete Response Letter
Alright Pharma Investors, today I am going to run through a comparison of some companies that all have drugs in development for Elderly patients with AML. What is surprising is that all of the drugs also either have completed or are in Phase II trials, but have yet to run a Phase III trial.
First up: Genzyme’s Clolar
I remember listening to the FDA panel meeting in disbelief when they voted against approving this drug back in September. At first I thought I was dreaming, but alas I came to my senses and realized that the FDA had actually voted » Read more: Who will get their Elderly AML drug approved first? Sunesis, Cyclacel, Genzyme, or Vion
© 2010 GekkoWire · Proudly powered by WordPress & Green Park 2 by Cordobo.
Valid XHTML 1.0 Transitional | Valid CSS 3
Twitter